A way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.
In research published in the medical journal Brain, Saint Louis University researcher Daniela Salvemini, Ph.D. and colleagues within SLU, the National Institutes of Health (NIH) and other academic institutions have discovered a way to block a pain pathway in animal models of chronic neuropathic pain including pain caused by chemotherapeutic agents and bone cancer pain suggesting a promising new approach to pain relief.
The scientific efforts led by Salvemini, who is professor of pharmacological and physiological sciences at SLU, demonstrated that turning on a receptor in the brain and spinal cord counteracts chronic nerve pain in male and female rodents. Activating the A3 receptor – either by its native chemical stimulator, the small molecule adenosine, or by powerful synthetic small molecule drugs invented at the NIH – prevents or reverses pain that develops slowly from nerve damage without causing analgesic tolerance or intrinsic reward (unlike opioids).
An Unmet Medical Need
Pain is an enormous problem. As an unmet medical need, pain causes suffering and comes with a multi-billion dollar societal cost. Current treatments are problematic because they cause intolerable side effects, diminish quality of life and do not sufficiently quell pain.
The most successful pharmacological approaches for the treatment of chronic pain rely on certain “pathways”: circuits involving opioid, adrenergic, and calcium channels.
For the past decade, scientists have tried to take advantage of these known pathways – the series of interactions between molecular-level components that lead to pain. While adenosine had shown potential for pain-killing in humans, researchers had not yet successfully leveraged this particular pain pathway because the targeted receptors engaged many side effects.
A Key to Pain Relief
In this research, Salvemini and colleagues have demonstrated that activation of the A3 adenosine receptor subtype is key in mediating the pain relieving effects of adenosine.
“It has long been appreciated that harnessing the potent pain-killing effects of adenosine could provide a breakthrough step towards an effective treatment for chronic pain,” Salvemini said. “Our findings suggest that this goal may be achieved by focusing future work on the A3AR pathway, in particular, as its activation provides robust pain reduction across several types of pain.”
The Latest on: Pain relief
via Google News
The Latest on: Pain relief
- Pain patients left in anguish by doctors 'terrified' of opioid addiction, despite CDC changeon June 24, 2019 at 1:54 pm
The guidelines "shouldn’t be used as a kind of cudgel to reduce appropriate prescribing." Many chronic pain patients question whether the revised policy will bring them relief. ... […]
- 1 in 3 Survivors Still in Pain Years After Cancer Treatmenton June 24, 2019 at 10:52 am
Years after undergoing cancer treatment, about 1 in 3 cancer survivors — which represents about 5 million Americans — report that they are still in pain. Half of them say the pain is severe enough to ... […]
- Cancer survivors are twice as likely to suffer from chronic painon June 24, 2019 at 10:05 am
“These results highlight the important unmet needs of pain management in the large ... the challenges faced by adolescent and young adults during and after cancer treatment that could uniquely impact ... […]
- Bangladesh 'Tree Man' wants hands amputated to relieve painon June 24, 2019 at 3:42 am
"I cannot bear the pain anymore. I can't sleep at night. I asked the doctors to cut off my hands so I can at least get some relief," he told AFP. His mother Amina Bibi supported the plea. "At least he ... […]
- Researchers estimate the prevalence of chronic pain among cancer survivorson June 24, 2019 at 12:01 am
Chronic pain is one of the most common long-term effects of cancer treatment and has been linked with an impaired quality of life, lower adherence to treatment, and higher health care costs. This ... […]
- The Superion Implant: The Best Back Pain Treatment You’ve Never Heard Ofon June 21, 2019 at 4:05 pm
Low back pain is one of the most debilitating conditions in the world. One 2010 study found that low back pain was the leading cause of disability worldwide, with nearly 10 percent of all adults ... […]
- Pain Relief Patches Market 2019 by Research Methodology, Value Chain Analysis and Distributors to 2024on June 21, 2019 at 5:35 am
Jun 21, 2019 (The Expresswire via COMTEX) -- The objectives of this study are to define, segment, and project the size of the Pain Relief Patches market based on company, product type, end user and ... […]
- One step closer to chronic pain reliefon June 20, 2019 at 7:50 am
Sortilin, which is a protein expressed on the surface of nerve cells, plays a crucial role in pain development in laboratory mice—and in all likelihood in humans as well. This is the main ... […]
- Global Topical Pain Relief Industry is further estimated to grow at a CAGR of 7.34% from 2019 to reach USD 13,468 Million by the year 2025on June 20, 2019 at 3:37 am
Jun 20, 2019 (AmericanNewsHour via COMTEX) -- Global Topical Pain Relief Industry was valued at USD 8.248 Million in the year 2018. Global Topical Pain Relief Industry is further estimated to grow at ... […]
- Study looks at pain relief for piglets from medicated mother's milkon June 17, 2019 at 6:54 am
New findings by researchers at the Kansas State University College of Veterinary Medicine suggest potential pain relief for piglets by administering medicine through the act of nursing. The ... […]
via Bing News